CrushSCI.com
177.2Average days
186Median days
30Fastest days
373Longest days
672025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

239 days

Comparative Effectiveness of Sacubitril/Valsartan Versus Sodium-Glucose Cotransporter 2 Inhibitors among Patients with Heart Failure with Reduced Ejection Fraction with or without Diabetes: A Cohort Study

Authors
Munaza Riaz; Steven M. Smith; David E. Winchester; Eric A. Dietrich; Haesuk ParkShow moreShow less
Affiliations
1. Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, USA; 2. Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, USA; 3. Division of Cardiovascular Medicine, Department of Medicine, College of Medicine, University of Florida, Gainesville, USA; 4. Department of Pharmacy Education and Practice, College of Pharmacy, University of Florida, Gainesville, USAShow moreShow less
Source PDF DOI Publisher page
68 days

When Methods Matter: An Umbrella Review of Lorundrostat and the Impact of Analytical Decisions on Reported Blood Pressure and Safety Outcomes

Authors
Zeyad Elariny; Omar Salem; Mohamad Ashraf Salaheldin; Adham Ahmed; Farida Rabie; Maryam Mohamed Sayed; Mohamed Harish; Mohamed Ali; Selim Ahmed Eliwa; Mohammad Elshorbagy; Sara ElHarouni; Ahmed Abdelmeguid; Retaj Ahmed; Omnia Azmy NabehShow moreShow less
Affiliations
1. Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, Egypt; 2. Faculty of Medicine, Benha National University, Obour City, Egypt; 3. Lecturer of Pharmacology, Kasr Al-Ainy Faculty of Medicine, Cairo University, Cairo, EgyptShow moreShow less
Source PDF DOI Publisher page
126 days

Aspirin Versus Clopidogrel as Single Antiplatelet Therapy After TAVI: A Propensity Score-Matched, Retrospective Analysis

Authors
Anastasios Apostolos; Konstantinos Konstantinou; Mohammed Allaf; Athanasios Sakalidis; Konstantinos Kalogeras; Ee Ling Heng; Simon Davies; Alison Duncan; Miles Dalby; Saeed Mirsadraee; Tarun Mittal; Aigul Baltabaeva; Tito Kabir; Mohammed Majid Akhtar; Robert Smith; Vasileios PanoulasShow moreShow less
Affiliations
1. Royal Brompton and Harefield Hospitals, Guy’s and St. Thomas’ NHS Foundation Trust, London, UK; 2. Faculty of Medicine, Imperial College London, London, UK; 3. National Heart and Lung Institute, Imperial College London, London, UKShow moreShow less
Source PDF DOI Publisher page
257 days

Empagliflozin in STEMI Patients: A Randomized Controlled Trial on Left Ventricular Recovery and Cardiovascular Outcomes

Authors
Fatemeh Baharvand; Roxana Mehran; Francesca Maria Di Muro; Alieh Mohammadi; Mohammadreza Aghajankhah; Shiva Parvaneh; Niloufar Akbari Parsa; Soheil Hassanipour; Ehsan Aboutaleb; Yaser Jenab; Somayeh Bashiri AliabadiShow moreShow less
Affiliations
1. Department of Cardiology, Healthy Heart Research Center, Heshmat Hospital, School of medicine, Guilan University of Medical Sciences, Rasht, Iran; 2. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, USA; 3. Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran; 4. Department of Pharmaceutics, School of pharmacy, Guilan University of Medical Sciences, Rasht, Iran; 5. Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IranShow moreShow less
Source PDF DOI Publisher page
105 days

Food Effects on the Pharmacokinetics of Single Dose and Steady-State Ralinepag, a Novel Oral Prostacyclin Agonist, in Healthy Volunteers

Authors
Daniel Lachant; Cristian E. Botta; George Giannakoulas; Natalie Patzlaff; Scott Seaman; Meredith Broderick; Maria Guido; Søren Mellemkjær; Zeenat SafdarShow moreShow less
Affiliations
1. University of Rochester Medical Center, Rochester, USA; 2. Department of Heart Failure and Pulmonary Arterial Hypertension, Sanatorio Privado San Gerónimo, Santa Fe, Argentina; 3. Aristotle University of Thessaloniki, Thessaloniki, Greece; 4. United Therapeutics Corp, Durham, USA; 5. UC Health, Cincinnati, USA; 6. Aarhus University Hospital, Aarhus, Denmark; 7. Houston Methodist Lung Center, Houston, USA; 8. HMRI, Houston, USA; 9. Weill Cornell College of Medicine, New York, USA; 10. Texas A&M College of Medicine, Bryan, USAShow moreShow less
Source PDF DOI Publisher page
373 days

Using Artificial Intelligence to Identify Patterns and Predictors of Adverse Drug Reactions in Cardiovascular Patients: A Comprehensive Narrative Review

Authors
Erfan Shahabinejad; Fatemeh Soflaei-Shahrbabak; Marzieh Gholami Shoa; Aida Azhdarimoghaddam; Mehrdad Mozafar; Pouya Yektaee-Rad; Samar Monajemi; Shayan Ghanouni; Shuhao Qiu; Mani Khorsand AskariShow moreShow less
Affiliations
1. Student Research Committee, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; 2. USERN Office, Rafsanjan University of Medical Sciences, Rafsanjan, Iran; 3. Faculty of Pharmacy, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran; 4. Student Research Committee, Zahedan University of Medical Sciences, Zahedan, Iran; 5. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran; 6. Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran; 7. Faculty of Medicine, Babol University of Medical Sciences, Babol, Iran; 8. Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; 9. Department of Medicine, University of Toledo, Toledo, USAShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does American Journal of Cardiovascular Drugs take to review a manuscript?

As of 2026-11-18, CrushSCI has 15 complete review records for American Journal of Cardiovascular Drugs. The fastest paper went from submission to acceptance in 30 days (Author’s Reply to: “Comment on: Colchicine for the Secondary Prevention of Cardiovascular Diseases: A Cumulative-Dose Meta-analysis of Randomized Controlled Trials Including 31,397 Subjects Worldwide”, received 2026-03-31, accepted 2026-04-30); the slowest took 373 days. The average is 177.2 days and the median is 186 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.